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Purpose of the study
Maraviroc (MVC) is one of newest antiretrovirals. Sev-
eral studies have assessed the impact of MVC on CD4
count, although few have analyzed it in clinical practice.
We assessed the immunological impact of MVC in clini-
cal practice in a university hospital.
Methods
Observational, retrospective, and cohort study in adult
outpatients taking antiretroviral therapy. We selected
two cohorts: the MVC cohort (MVCC), comprising
patients who had switched to MVC between 01/05/2008
and 31/07/2009, and the last-generation antiretroviral
cohort (LGAC), comprising patients who had switched
to darunavir, etravirine, and/or raltegravir during the
same period. The primary endpoint was the increase in
CD4 count at 48 weeks.
Results
The MVCC included 21 patients and the LGAC 56.
Only 18 of the 21 patients were finally analyzed, as 3
patients stopped MVC and did not reach 48 weeks.
There were no differences in age (median MVCC, 46.93
years; LGAC, 45.43 years) or sex (MVCC, 66.1% men;
LGAC, 61.9% men) between the cohorts. HIV was mul-
tidrug-resistant (genotypic resistance to drugs of ≥2
classic families and/or extensive experience with 3 clas-
sic families) in 73.2% of LGAC and 95.2% of MVCC
(p=0.094). Adherence during the previous year of treat-
ment with MVC was >90% in 85.7% of MVCC and
76.6% in LGAC. There were no significant differences
between the cohorts. Raltegravir was included in the
regimen in 86% of the MVCC and in 89% of the LGAC.
At baseline, viral load was undetectable (defined as <50
copies/ml) in 19% of the MVCC and 51.8% of the
LGAC (p=0.02). At the end of follow-up (48 weeks),
viral load was undetectable in 90.5% of the MVCC and
in 85.7% of the LGAC (p=0.86). At baseline, the mean
CD4 count was 362.67 in the MVCC and 365.64 in the
LGAC (p=0.96); at the end of follow-up, these values
were 507.24 (95% CI, 377.40-637.08) and 462.07 (95%
CI, 367.14-556.99) for MVCC and LGAC, respectively,
with a mean difference of 45 cells (95% CI, “C126.80 to
217.14). The mean increase in CD4 count was 145 cells
(95% CI, 126.80 to 296.17) vs. 96 cells (95% CI, 30.44 to
223.30)
Conclusions
An increase in the immune response was observed in
both cohorts at 48 weeks of follow-up. Although the
increase in CD4 count was higher in the MVCC, signifi-
cant differences were not found.
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